Navigation Links
Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
Date:12/22/2011

SAN DIEGO, Dec. 22, 2011 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the completion of its public offering of 5,646,173 units.  Each unit consisted of one share of common stock and a warrant to purchase ten shares of common stock, at a price to the public of $1.45 per share of common stock and $1.449 per warrant to purchase each share of common stock, which together comprised the purchase price of $15.94 per unit.   Net proceeds, after underwriting discounts and commissions and estimated expenses, were approximately $86.9 million.  The underwriter does not have an option to purchase any additional units in this offering. Leerink Swann LLC acted as sole manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 17, 2009.  The offering was made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained from Leerink Swann LLC , Attention: Syndicate Department, One Federal Street, 37th Fl., Boston, MA 02110 or by calling Leerink Swann LLC, toll free, at 1-800-808-7525, Ext. 4814.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

 

 

 


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
2. Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
4. Orexigen® Therapeutics Provides a Regulatory Update on Contrave® NDA
5. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
6. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
7. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
8. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
11. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... PHIA) and Volcano Corporation (NASDAQ: VOLC ), a ... applications, today announced that they have entered into a definitive ... tender offer to acquire all of the issued and outstanding ... total equity purchase price of USD 1 billion (approx. EUR ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... July 5, 2011 Allure Medical Spa released an ... and to help them visualize potential outcomes. "Many of ... the newest treatments," explains board certified cosmetic surgeon, Dr. ... digital resource in the palm of their hands that ...
... 5, 2011 Dr. Michael Lowenstein, co-medical director of ... detoxification under deep sedation, is expressing grave concern over ... alarming rise in number of individuals seeking treatment for ... The new national analysis from the U.S. ...
Cached Medicine Technology:Cosmetic Surgery iPhone App Teaches and Amuses 2Waismann Method Medical Director Cautions of Increasing Numbers of Opioid Addicts 2
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- New research warns parents that ... lives at risk. Nearly half of teen drivers killed in ... were at least 11 years old and often lacked important safety ... Eighty-two percent of teen drivers killed in crashes were in cars ... to 10 years old, 31 percent were in cars 11 to ...
(Date:12/19/2014)... All children should have their eyesight checked between the ... experts say. The new vision-screening guidelines for preschool-aged ... National Center for Children,s Vision Health. The panel ... for eye problems, particularly vision issues that require ... strabismus (a disorder of eye alignment). Early detection ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- Injectable drug users who ... suicide attempt rate of other substance users, a new ... associated with the risk of suicide attempt and completed ... of Montreal, said in a university news release. "However, ... wanted to know who among substance users were actually ...
(Date:12/19/2014)... 2014 (HealthDay News) -- The cost of cancer treatment ... new study finds. Researchers examined data from 1,000 ... with colorectal or lung cancer. Of those patients, almost ... more than 100 had advanced cancer. Nearly half ... their medical bills, which was linked with a poorer ...
Breaking Medicine News(10 mins):Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2
... to Follow Dispute Resolution Process is ... the Most Expeditious Path to Final Approval -, ... DDS;,NASDAQ: DDSS) today announced that it has appealed the ... tramadol formulation to,the next supervisory level under the FDA,s ...
... -- Simcere,Pharmaceutical Group (NYSE: SCR ), a ... manufacturer of the patented,anti-cancer biotech product Endu in ... & Co.,s Fourth Investor Tour of China,being held ... 4, 2008 in Beijing,Shenzhen and Shanghai., Simcere,s ...
... New Consumer Label, WICHITA, Kan., April 1, ... that include new best practices,animal husbandry, biosecurity, and ... by VeriPrime, Inc., of Wichita, KS, at the,recommendation ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080401/AQTU070LOGO ), The Advisory Council ...
... Fork, Care and Prevention, WICHITA, Kan., April ... and higher new safety standards, including protections,against E. ... leading farmers and,ranchers behind the food safety seal, ... Citing growing consumer concern over food safety ...
... and OTTAWA, April 1, 2008 Natural,Nutrition, Inc. ... that its operating,subsidiary, InterACTIVE Nutrition, Inc. (INII) achieved ... million (CDN) in EBITDA for the,year ended December ... Nutrition, stated, "We are pleased to,report record results ...
... China,Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN ) ... the research, development, manufacture,and marketing of pharmaceutical, nutritional ... China ("PRC"), announced its financial,results for full year ... 2007 Highlights -- Net sales totaled ...
Cached Medicine News:Health News:Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy 2Health News:Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy 3Health News:Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.'s Fourth Investor Tour of China 2Health News:VeriPrime Approves New Best Practices for Beef Production 2Health News:VeriPrime Approves New Best Practices for Beef Production 3Health News:'VeriPrime Certified Safeguards' Food Safety Label Unveiled 2Health News:'VeriPrime Certified Safeguards' Food Safety Label Unveiled 3Health News:Natural Nutrition Subsidiary Reports Record Year-End Revenue and EBITDA 2Health News:China Shenghuo Reports Full Year 2007 Financial Results 2Health News:China Shenghuo Reports Full Year 2007 Financial Results 3Health News:China Shenghuo Reports Full Year 2007 Financial Results 4Health News:China Shenghuo Reports Full Year 2007 Financial Results 5Health News:China Shenghuo Reports Full Year 2007 Financial Results 6Health News:China Shenghuo Reports Full Year 2007 Financial Results 7Health News:China Shenghuo Reports Full Year 2007 Financial Results 8Health News:China Shenghuo Reports Full Year 2007 Financial Results 9Health News:China Shenghuo Reports Full Year 2007 Financial Results 10Health News:China Shenghuo Reports Full Year 2007 Financial Results 11Health News:China Shenghuo Reports Full Year 2007 Financial Results 12Health News:China Shenghuo Reports Full Year 2007 Financial Results 13
Mini-Finesse 5mm Dilating Trocar, hook electrode, two lengths, mini or basic kit....
Thoracoscopy Cannula, reusable, hook electrode, two lengths, mini or basic kit....
... Sleeve consists of a rounded ... to prevent puncture or laceration ... cavity has been entered. The ... the sleeve which enhance security ...
... three separate components: an exchange rod, a dilating ... trocar sleeve. The exchange rod is a rigid ... The dilating obturator is tapered and threaded at ... created by the 10/11mm or the 12mm ENDOPATH ...
Medicine Products: